{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:10:40Z","timestamp":1787008240161,"version":"build-2736575974"},"reference-count":51,"publisher":"SAGE Publications","issue":"16","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Antioxidants &amp; Redox Signaling"],"published-print":{"date-parts":[[2018,6]]},"abstract":"<jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>\n                      Shortly after the discovery of the role of hydrogen sulfide (H\n                      <jats:sub>2<\/jats:sub>\n                      S) in many physiological and pathological processes, attempts were made to develop novel pharmaceuticals that may be of benefit for treatment or prevention of a wide range of disorders. The promise of H\n                      <jats:sub>2<\/jats:sub>\n                      S-based therapeutics is now being demonstrated in clinical trials.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Advances:<\/jats:title>\n                    <jats:p>\n                      H\n                      <jats:sub>2<\/jats:sub>\n                      S-releasing drugs, such as SG1002 for cardiovascular disorders, and ATB-346 for arthritis, have progressed into clinical trials and have shown considerable promise. Some older drugs, such as zofenopril, have now been recognized to produce at least some of the beneficial effects through release of H\n                      <jats:sub>2<\/jats:sub>\n                      S.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Critical Issues:<\/jats:title>\n                    <jats:p>\n                      There remains a need to better understand the underlying mechanisms for some of the observed effects of H\n                      <jats:sub>2<\/jats:sub>\n                      S-releasing drugs in a clinical setting, such as the marked increase in analgesic potency that has been observed with ATB-346.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Future Directions:<\/jats:title>\n                    <jats:p>\n                      The proof-of-concept clinical studies reviewed herein pave the way for examination, in a clinical setting, of several other potential applications of H\n                      <jats:sub>2<\/jats:sub>\n                      S-based drugs in a wide range of disorders, including diabetes, hypertension, and cancer chemoprevention.\n                      <jats:italic toggle=\"yes\">Antioxid. Redox Signal.<\/jats:italic>\n                      28, 1533\u20131540.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/ars.2017.7068","type":"journal-article","created":{"date-parts":[[2017,4,8]],"date-time":"2017-04-08T00:04:59Z","timestamp":1491609899000},"page":"1533-1540","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":116,"title":["Hydrogen Sulfide-Releasing Therapeutics: Translation to the Clinic"],"prefix":"10.1177","volume":"28","author":[{"given":"John L.","family":"Wallace","sequence":"first","affiliation":[{"name":"University of Calgary","place":["Canada"]},{"name":"Antibe Therapeutics, Inc.","place":["Canada"]},{"name":"Universidade Camilo Castelo Branco","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Vaughan","sequence":"additional","affiliation":[{"name":"Antibe Therapeutics, Inc.","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Dicay","sequence":"additional","affiliation":[{"name":"University of Calgary","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wallace K.","family":"MacNaughton","sequence":"additional","affiliation":[{"name":"University of Calgary","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilberto","family":"de Nucci","sequence":"additional","affiliation":[{"name":"Universidade Camilo Castelo Branco","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2018,6,1]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.16-03-01066.1996"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.niox.2014.12.013"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.114.301475"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0035196"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2014.05.008"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1586\/erc.12.81"},{"key":"e_1_3_2_8_2","unstructured":"Boucher M. A Bayesian meta-analysis of longitudinal data in placebo controlled studies with naproxen. 2008. www.page-meeting.org\/pdf_assets\/8269-Bayesian%20Meta%20Analysis%20Final.pdf"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1080\/AC.67.1.2146570"},{"key":"e_1_3_2_10_2","first-page":"A528","article-title":"The angiotensin converting enzyme inhibitor zofenoprilat prevents endothelial cell apoptosis and promotes coronary angiogenesis \u201cin vitro.\u201d","volume":"13","author":"Brogelli L","year":"1999","unstructured":"Brogelli L, , Parenti A, , Capaccioli S, , Brogelli L, , Tricarico C, , Villari D, , and Pazzagli M. The angiotensin converting enzyme inhibitor zofenoprilat prevents endothelial cell apoptosis and promotes coronary angiogenesis \u201cin vitro.\u201d. FASEB J, 13: A528, 1999.","journal-title":"FASEB J"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvu026"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-011-1029-0"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm901638j"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199203000-00005"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199732040-00002"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2016.10.019"},{"key":"e_1_3_2_17_2","first-page":"909","article-title":"Preclinical pharmacology of zofenopril, an inhibitor of antiotensin I converting enzyme","volume":"19","author":"DeForrest JM","year":"1989","unstructured":"DeForrest JM, , Waldron TL, , Krapcho J, , Turk C, , Rubin B, , Powell JR, , Cushman DW, , and Pertrillo EW. Preclinical pharmacology of zofenopril, an inhibitor of antiotensin I converting enzyme. J Cardiovasc Pharmacol, 19: 909\u2013915, 1989.","journal-title":"J Cardiovasc Pharmacol"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.003531"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1177\/147323000503300103"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00105.2011"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.90566.2008"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1089\/ars.2014.5933"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13618-015-0025-3"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1089\/ars.2012.4944"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-1906"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2012.10.019"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.332.7553.1302"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1321871111"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.000855"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2012.04.011"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2006.12.011"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/480921"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2004.03.025"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0147289"},{"key":"e_1_3_2_35_2","first-page":"768607","article-title":"The cardioprotective actions of hydrogen sulfide in acute myocardial infarction and heart failure","volume":"2014","author":"Polhemus DJ","year":"2014","unstructured":"Polhemus DJ, , Calvert JW, , Butler J, , and Lefer DJ. The cardioprotective actions of hydrogen sulfide in acute myocardial infarction and heart failure. Scientifica (Cairo), 2014: 768607, 2014.","journal-title":"Scientifica (Cairo)"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/1755-5922.12128"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00044.2012"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pa.32.040192.000545"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3565(25)38194-2"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3466.1999.tb00008.x"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/bph.12369"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2425"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.2174\/092986712803413962"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.niox.2014.11.001"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199109000-00016"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4433"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2009.00611.x"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.11.042"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-013-2777-8"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1186\/ar1854"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.885.3.7"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/20.21.6008"}],"container-title":["Antioxidants &amp; Redox Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/ars.2017.7068","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/ars.2017.7068","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/ars.2017.7068","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:54:53Z","timestamp":1777377293000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/ars.2017.7068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":51,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["10.1089\/ars.2017.7068"],"URL":"https:\/\/doi.org\/10.1089\/ars.2017.7068","relation":{},"ISSN":["1523-0864","1557-7716"],"issn-type":[{"value":"1523-0864","type":"print"},{"value":"1557-7716","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6]]}}}